HIV and tuberculosis coinfection: Inextricably linked liaison

Journal of the National Medical Association

Volumn 99, Issue 12, 2007, Pages 1414-1419

  Idemyor, Vincent ^a,b,c,d  

^a UNIVERSITY OF PORT HARCOURT   (Nigeria)

^b AHMADU BELLO UNIVERSITY   (Nigeria)

^c UNIVERSITY OF ILLINOIS   (United States)

^d NONE   (United States)

Author keywords

Drugs; HIV AIDS; Tuberculosis

Indexed keywords

AMIKACIN; CAPREOMYCIN; COTRIMOXAZOLE; EFAVIRENZ; ISONIAZID; KANAMYCIN; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

AFRICA SOUTH OF THE SAHARA; ANTIBIOTIC THERAPY; DRUG INDICATION; FUNDING; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MEDICAL RESEARCH; MIXED INFECTION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SHORT COURSE THERAPY; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

AFRICA SOUTH OF THE SAHARA; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; COMORBIDITY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HIV INFECTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 37349034996     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2007. Geneva, Switzerland: World Health Organization; 2007.
2. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009-1021.
3. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS. 2001;15:143-152.
4. De Cock KM, Soro B, Coulibaly IM, et al. Tuberculosis and HIV infection in sub-Saharan Africa. JAMA. 1992;268:1581-1587.
5. Elliot AM, Halwiindi B, Hayes RJ, et al. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. J Trop Med Hyg. 1993;96:1-11.
6. Githui W, Nunn P, Juma ES. Cohort study of HIV-positive and HIV-negative tuberculosis patients, Nairobi, Kenya: comparison of bacteriological results. Tuber Lung Dis. 1992;73:203-209.
7. Johnson JL, Vjecha MJ, Okwera A, et al. Impact of human immunodefiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda. Int J Tuberc Lung Dis. 1998:2:397-404.
8. Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a west African city. AIDS. 1993;7:1569-1579.
9. Rana FS, Hawken MP, Mwachari C, et al. Autopsy study of HIV-1 positive and HIV-1 negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr. 2000;24:23-29.
10. Ansari NA, Kombe AH, Kenyon TA, et al. Pathology and causes of death in a group of 128 predominantly HIV positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis. 2002;6:55-63.
11. Munyati SS, Dhoba T, Makanza ED, et al. Chronic cough in primary health care attendees, Harare, Zimbabwe: diagnosis and impact of human immunodeficiency virus. Clin Infect Dis. 2005;40:1818-1827.
12. Churchyard GJ, Kleinschmidt I, Corbett EL, et al. Mycobacterium disease in South African gold miners in the era of HIV infection. Int J Tuberc Lung Dis. 1999;3:791-798.
13. Grant AD, Djomand G, De Cock KM. Natural history and spectrum of disease in adults with HIV/AIDS in Africa. AIDS. 1997;11(suppl B):S43-S54.
14. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach '2006 revision). Geneva: World Health Organization; 2006.
15. Dye C, Watt CJ, Bleed D. Low access to a highly effective therapy: a challenge for international tuberculosis control. Bull World Health Organ. 2002;80:437-444.
16. Maher D, Borgdorff M, Boerma T. HIV-related tuberculosis: how well are we doing with current control efforts? Int J Tuberc Lung Dis. 2005;9:17-24.
17. Harries AD, Hargreaves NJ, Gausi F, et al. High death rates in health care workers and teachers in Malawi. Trans R Soc Trop Med Hyg. 2002;96(1):34-37.
18. Perkins MD, Roscigno G, Zumla A. Progress towards improved tuberculosis diagnostics for developing countries. Lancet. 2006;367:942-943.
19. Harries AD, Hargreaves NJ, Kwanjana JH, et al. Clinical diagnosis of smear-negative pulmonary tuberculosis: an audit of diagnostic practice in hospitals in Malawi. Int J Tuberc Lung Dis. 2001;12:1143-1147.
20. Chintu C, Mwaba P. Tuberculosis in children with human immunodeficiency virus infection. Int J Tuberc Lung Dis. 2005;5:477-484.
21. Greenberg AE, Lucas S, Tossou O, et al. Autopsy-proven causes of death in HIV-infected patients treated for tuberculosis in Abidjan, Côte d'Ivoire. AIDS. 1995;9:1251-1254.
22. Lewis DK, Whitty CJ, Walsh AL, et al. Treatable factors associatec with severe anaemia in adults admitted to medical wards in Blantyre, Malawi, an area of high HIV seroprevalence. Trans R Soc Trop Med Hyg. 2005;8:561-567.
23. Hawken M, Nunn P, Gathua S, et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet. 1993;342(8867):332-337.
24. Elliot AM, Halwiindi B, Hayes RJ, et al. The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia. J Trop Med Hyg. 1995;98(1):9-21.
25. Sonnenberg P, Murray J, Glynn JR, et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 2001;58(9294):1687-1693.
26. Dorman SE, Chaisson RE. From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat Med. 2007;13:295-298.
27. Martinson N, Hale M, Karstaedt A, et al. Causes of Death in HIV-infected Adults with TB Admitted to 2 Hospitals in Soweto, South Africa. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles, CA. Abstract 82.
28. Harries AD, Chimzizi R, Zachariah R. Safety, effectiveness, and outcomes of concomitant use of highly active antiretroviral therapy with drugs for tuberculosis in resource-poor settings. Lancet. 2006;367:944-945.
29. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS. 2002;16:75-83.
30. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359(9323):2059-2064.
31. Burman WJ, Gallicano K, Peloquin C. Therapeutic Implications of Drug Interactions in the Treatment of Human Immunodeficiency Virus-Related Tuberculosis. Clin Infect Dis. 1999;28:419-430.
32. Kwara A, Flanigan TP, Carter EJ. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. Int J Tuberc Lung Dis. 2005;9:248-257.
33. Manosuthi W, Ruxrungtham K, Likanonsakul S, et al. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis. 2007;44:141-144.
34. Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquic Immune Defic Syndr. 2001;28:450-453.
35. Lawn S, Myer L, Bekker LG, Wood R. Early Mortality among Patients with HIV-associated TB in Africa: Implications for the Time to initiate ART. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles, CA. Abstract 81.
36. Lawn SD, Gail-Bekker L, Miller R. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis. 2005;5:361-373.
37. Lawn S, Myer L, Bekker LG, et al. TB-associafed Immune Reconstitution Disease: Incidence, Risk Factors, and Effect within an ART Program in subSaharan Africa. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles, CA. Abstract 863.
38. Fitzgerald DW, Desvarieux M, Severe P, et al. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1 infected individuals: a randomized trial. Lancet. 2000;356(9240):1470-1474.
39. Churchyard GJ, Fielding K, Charalambous S, et al. Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS. 2003;17(14):2063-2070.
40. Cohen T, Lipsitch M, Walensky RP, et al. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci USA. 2006;103(18):7042-7047.
41. Witktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprimsulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet. 1999;353(9163):1469-1475.
42. Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet. 2004;364(9443):1428-1434.
43. Chintu C, Bhat GJ, Walker AS, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomized placebo-controlled trial. Lancet. 2004;364(9448):1865-1871.
44. Zachariah R, Massaquoi M. Cotrimoxazole prophylaxis for HIV-positive TB patients in developing countries. Trop Doct. 2006;36(2):79-82.
45. Weyer K. Transmission of Extensively Drug-resistant TB in South Africa and Implications for Infection Control in Health Care Settings. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles, CA. Abstract 8.
46. Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep. 2006;55:1176.